Tag Archives: Watchman

Resultados a 5 años del cierre de orejuela

Five-Year Outcomes for Appendage Closure

Five-Year Outcomes for Appendage Closure

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure with the Watchman device was equivalent to warfarin for preventing stroke in atrial fibrillation, but it had a high rate of peri-procedural complications. The follow-up randomized trial was PREVAIL (Evaluation of the

TCT 2017 | Resultados finales del dispositivo Watchman

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

Courtesy of SBHCI. The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke prevention rate to that of warfarin, though with a clear reduction in bleeding. The meta-analysis showed a significant reduction in hemorrhagic stroke (0.17% vs 0.87%), non-procedure related